title: A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.
abstract: OBJECTIVE
  Ultra low doses of interleukin-2 (IL-2) can activate the high-affinity IL-2 receptor constitutively expressed on CD56(bright) natural killer (NK) cells, the CD34+ NK cell precursor, and CD4+ CD25+ regulatory T cells (Tregs) in vivo. We have previously shown synergy between IL-2 and stem cell factor (SCF) in the generation of CD56(bright) NK cells from CD34+ hemopoietic progenitor cells in vitro and showed synergistic NK cell expansion in an in vivo preclinical model. To determine the safety, toxicity, and immune modulation of this combination of cytokines in vivo, we conducted a first-in-man phase I study.
  
  
  METHODS
  A phase I dose escalation study was conducted using IL-2 at 900,000 or 650,000 IU/m2/d for 8 weeks with 5 or 10 microg/kg/d of SCF given thrice a week for 8 weeks in patients with HIV infection and/or cancer.
  
  
  RESULTS
  Ten of 13 patients completed therapy; four experienced the dose-limiting toxicities of grade 3 fatigue or urticaria. The maximum tolerated doses of IL-2 and SCF in combination is 650,000 IU/m2/d of IL-2 and 5 microg/kg/d thrice a week of SCF. NK cells were expanded over 2-fold on therapy; Tregs were expanded nearly 6-fold from baseline.
  
  
  CONCLUSIONS
  Administration of IL-2 with SCF is safe and well tolerated and leads to expansion of lymphocyte subsets in patients with HIV or HIV and cancer; however, the changes in NK cell and Treg expansion seen with this cytokine combination were no different than those seen with a similar dose of IL-2 alone.
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Ohio State University, Columbus, USA. manisha.shah@osumc.edu
authors.forename: Manisha H
authors.initials: MH
authors.lastname: Shah
authors.forename: Aharon G
authors.initials: AG
authors.lastname: Freud
authors.forename: Don M
authors.initials: DM
authors.lastname: Benson
authors.forename: Amy K
authors.initials: AK
authors.lastname: Ferkitich
authors.forename: Bruce J
authors.initials: BJ
authors.lastname: Dezube
authors.forename: Zale P
authors.initials: ZP
authors.lastname: Bernstein
authors.forename: Michael A
authors.initials: MA
authors.lastname: Caligiuri
mesh_terms: D000328:Adult; D019002:CD56 Antigen / Q000276:immunology; D015331:Cohort Studies; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D064420:Drug-Related Side Effects and Adverse Reactions; D006678:HIV / Q000187:drug effects*; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D012074:Remission Induction; D019089:Stem Cell Factor / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D019002:CD56 Antigen; D007376:Interleukin-2; D019089:Stem Cell Factor